

LIFEMARK HEALTH TRANSACTION DETAILS

*A detailed look into the transaction and what effects it has on
Alaris' current and future financial position*

May 6, 2011

For more information contact:

Curtis Krawetz

Manager of Investor Relations & Investment Analyst

Alaris Royalty Corp.

Ph 1-403-221-7305

ckrawetz@alarisroyalty.com

232, 2031 33rd Avenue SW

Calgary AB, Canada

T2T 1Z5

www.alarisroyalty.com



FORWARD LOOKING STATEMENTS

This presentation contains forward-looking statements. Statements other than statements of historical fact contained in this presentation may be forward-looking statements, including, without limitation, management's expectations, intentions and beliefs concerning the closing of the Transaction, the expected Distribution, Centric's pro forma cash flow and EBITDA, the expected increase in the Company's distributable cash, the use of the Proceeds, including the Company's ability to reinvest the Proceeds in new and existing private company partnerships at historic average multiples on a timely basis, the repayment of debt, the benefits of the Transaction, Alaris' future revenue stream, the Company's expected growth, the Company's performance and business prospects and opportunities of the Company, and the Company's business strategy. Many of these statements can be identified by looking for words such as "believe", "expects", "will", "intends", "projects", "anticipates", "estimates", "continues" or similar words or the negative thereof. There can be no assurance that the plans, intentions or expectations upon which these forward looking statements are based will occur.

Statements containing forward-looking information by their nature involve numerous assumptions and significant known and unknown facts and uncertainties of both a general and a specific nature. Key assumptions include, but are not limited to assumptions that: the Transaction will be completed on the terms and conditions set out in the arrangement agreement, the Canadian and U.S. economies will continue to grow moderately in 2011; the Company will be able to identify and close new opportunities with new and existing Private Company Partners; interest rates will remain stable; more private companies will require access to alternative sources of capital; and capital markets will continue to improve. In determining the Company's expectations for economic growth, management primarily considers historical economic data provided by the Canadian and U.S. governments and their agencies. The information contained in this presentation, including the information set forth under the heading "*Risk Factors*" in the Company's Annual Information Form dated March 25, 2011 (a complete copy of which can be found on SEDAR at www.sedar.com) identifies additional factors that could affect the operating results and performance of the Company and may cause the actual results of the Company to differ materially from those anticipated in forward-looking statements.

Forward-looking statements are subject to risks, uncertainties and assumptions and should not be read as guarantees or assurances of future performance. Accordingly, readers are cautioned not to place undue reliance on any forward-looking information contained in this presentation as a number of factors could cause actual future results, conditions, actions or events to differ materially from the targets, expectations, estimates or intentions expressed in the forward-looking statements. Statements containing forward-looking information reflect management's current beliefs and assumptions based on information in its possession on the date of this presentation. Although management believes that the expectations represented in such forward-looking statements are reasonable, there can be no assurance that such expectations will prove to be correct.

The forward-looking statements contained herein are expressly qualified in their entirety by this cautionary statement. The forward-looking statements included in this presentation are made as of the date of this presentation and Alaris does not undertake or assume any obligation to update or revise such statements to reflect new events or circumstances except as expressly required by applicable securities legislation.

NON-GAAP MEASURES

The terms EBITDA, earnings coverage & distributable cash per share (collectively the "**Non-GAAP Measures**") are financial measures used in this presentation that are not standard measures under Canadian generally accepted accounting principles ("**GAAP**"). The Company's method of calculating the Non-GAAP Measures may differ from the methods used by other issuers. Therefore, the Company's Non-GAAP Measures may not be comparable to similar measures presented by other issuers.

EBITDA refers to net earnings (loss) determined in accordance with GAAP, before depreciation and amortization, net of gain or loss on disposal of capital assets, interest expense and income tax expense. EBITDA is used by management and many investors to determine the ability of an issuer to generate cash from operations. Management believes EBITDA is a useful supplemental measure from which to determine the Company's ability to generate cash available for debt service, working capital, capital expenditures, income taxes and dividends.

Management of Alaris uses an annual **earnings coverage ratio** (the "**Earnings Coverage Ratio**") to evaluate the ability for one of its Private Company Partners to pay its distributions to Alaris. The Earnings Coverage Ratio is defined as EBITDA divided by interest, principal repayments, maintenance capital expenditures, and distributions to Alaris.

Distributable cash per share ("DCPS") means Alaris' net income prepared in accordance with GAAP excluding non-cash items that include stock-based compensation expense, future income taxes, and depreciation and amortization divided by the weighted average number of Common Shares issued and outstanding in the share capital of the Company over such period.

ELIGIBLE DIVIDENDS

All dividends are designated by the Company to be eligible dividends for the purpose of the Income Tax Act (Canada) and any similar provincial or territorial legislation.

DATE OF PRESENTATION

Information contained herein is given as of May 6, 2011, unless otherwise stated.

DEFINITIONS USED IN THIS DOCUMENT

- Alaris Royalty Corp. (“**Alaris**” or the “**Company**”)
- LifeMark Health Limited Partnership (“**LifeMark Health**” or “**LifeMark**” or the “**Partnership**”)
- MEDIchair Inc. (“**MEDIchair**”)
- LifeMark and MEDIchair (collectively the “**LifeMark Group**”)
- Centric Health Corporation (“**Centric**” or “**Centric Health**”)
- The transaction in which Alaris will receive \$65 million in cash from Centric for approximately half of Alaris’ financial interests in the LifeMark Group (the “**Transaction**”)
- The cash total of \$65 million in which Centric is paying Alaris at closing of the Transaction (the “**Proceeds**”)
- Centric has the right to exercise an option to purchase Alaris’ remaining financial interests in LifeMark upon the second anniversary of closing the Transaction for \$65.5 million (the “**Purchase Option**”)
- LifeMark’s \$6.75 million annual payment to Alaris following closing of the Transaction (the “**Distribution**”)
- The amount Alaris expected to receive from the LifeMark Group in 2011 prior to the Transaction was \$13.50 million (the “**Pre-Transaction Distribution**”)
- Management of Alaris uses distributable cash per share (“**DCPS**”) to measure its payout ratio and the level of accretion new partnerships have on Alaris’ cash available to distribute to shareholders by way of a monthly dividend (see Non-GAAP Measures on page 3 for definition of DCPS calculation).
- Management of Alaris uses an annual earnings coverage ratio (the “**Earnings Coverage Ratio**”) to evaluate the ability for one of its Private Company Partners to pay its distributions to Alaris. The Earnings Coverage Ratio is defined by Alaris as EBITDA divided by interest, principal repayments, maintenance capital expenditures, and distributions to Alaris.

SECTION I - EXECUTIVE SUMMARY

- The total implied value of the Transaction is \$130.5 million and consists of:
 - **\$65 million cash at closing** paid to Alaris for a portion of its financial interest in LifeMark Health and 100% of its financial interest in MEDChair.
 - **\$65.5 million Purchase Option** granted to Centric in which it can elect to purchase Alaris' remaining interests in LifeMark Health upon the second anniversary following closing of the Transaction (see page 7 for more details).
- Alaris will continue to receive a \$6.75 million annual Distribution from LifeMark Health, representing approximately 50% of the Pre-Transaction Distributions received from the LifeMark Group.
- The new Distribution has a guaranteed increase of 4% per year which will be applied to the previous year's Distribution on each anniversary of the Transaction.
- Upon closing of the Transaction, Alaris will have received total cash payments to date of \$123 million from the LifeMark Group as well as a retained value in LifeMark equal to \$65.5 million on total capital invested of \$74 million (over a six year period).
- Centric Health will now be a guarantor on the Distribution from LifeMark to Alaris. The larger consolidated income of Centric (which will include LifeMark's income) will result in a significant increase to the Earnings Coverage Ratio on the Distribution Alaris will receive from LifeMark.
- \$65 million of cash Proceeds represent approximately 10x the portion of the 2010 distributions from the LifeMark Group which have been sold in this Transaction. Reinvesting those Proceeds at or near Alaris' historic average of 6x (16.7%) would result in a significant increase in DCPS.
- Alaris will have a more balanced revenue base going forward as the Transaction significantly reduces the weight LifeMark had on Alaris' total revenue taking it from 60% to 43% immediately following the Transaction, and significantly lower once the \$65 million of Proceeds have been contributed to new or existing partnerships (see page 10 for more information on revenue weights).
- LifeMark will continue to be Alaris' largest source of revenue and a very meaningful partner as Alaris continues to grow.
- Alaris' Board of Directors has determined to maintain its dividend payment of \$0.085/share (\$1.02 annualized).

SECTION II - SOURCES AND USES OF PROCEEDS

Source:

- Centric Health will pay Alaris \$65 million upon closing of the Transaction.
- Centric is a premier provider of a wide range of healthcare services in Canada and is listed on the Toronto Stock Exchange (TSX: CHH). Centric has been, and will continue to be, a consolidator of the Healthcare industry in Canada and is led by a management team and board of directors with the capability and experience needed to be successful in the industry.
- By combining with LifeMark, Centric Health will have a platform for delivering care in more than 670 locations across Canada and will become one of the largest integrated providers of healthcare in the Country.
- The Transaction will make for Centric and LifeMark combined pro forma annual revenues in excess of \$300 million in 2011 as well as the potential to provide for both service, and cost saving synergies.
- Following the closing of the Transaction, Craig Gattinger and Ron Lowe, CEO and President of LifeMark respectively, will lead and develop the Rehabilitation, Elder Care, Medical Assessment and Disability Management component of Centric Health along with their experienced leadership team and staff.

Uses:

- Alaris' number one priority is to reinvest the Proceeds from the Transaction into new, or existing, Private Company Partners. Management of Alaris is confident that this can be done in a timely manner in order to maximize the benefits that the full reinvestment of Proceeds can have on shareholder value.
- Immediately following the Transaction, Alaris will pay down its current revolving credit facility (the "Facility") in full, which currently has an outstanding balance of \$26.2 million.
- The debt repayment will lead to an immediate annual interest savings of \$1.7 million.
- After the Facility is paid down, Alaris will have over \$38.5 million of cash and an unused Facility of \$30 million at its disposal to fund new and existing private company partnerships.

Sources		Uses	
Cash from Centric	\$65.0	Repay debt	\$26.2
		Fees	\$0.3
		Cash held	\$38.5
TOTAL	\$65.0	TOTAL	\$65.0

SECTION III - TERMS OF CONTINUED PARTNERSHIP WITH LIFE MARK HEALTH

Alaris has negotiated new terms on its remaining financial interest in LifeMark Health. These terms will significantly increase the visibility to shareholders on both the annual Distribution paid as well as the potential exit value on the remaining financial interests - if Centric so chooses to exercise the Purchase Option on these interests.

Details of Continued Distribution Terms:

- The \$6.75 million annual Distribution will continue to be paid monthly.
- The Distribution will increase by a guaranteed 4% per year commencing on the 1st anniversary of the closing of the Transaction.
- Historically, LifeMark's percentage change in "same clinic sales" was used to calculate the reset on Alaris' Distribution. This metric changed from a low of -1.1% to a high of +5.6% since 2005.
- The Distribution is now approximately half of the Pre-Transaction Distribution from the LifeMark Group and will now be guaranteed by Centric Health's much larger consolidated income. These two factors significantly enhance the Earnings Coverage Ratio on Alaris' Distribution from LifeMark, which leads to an increased certainty of revenue from an already very reliable source of revenue for Alaris.

Details of Purchase Option:

- Centric has the option to purchase the remaining financial interest in LifeMark from Alaris on the second anniversary from the date of the Transaction closing.
- Centric has a year following the 2nd anniversary of the Transaction to exercise this Purchase Option for \$65.5 million.
- If the Purchase Option is not exercised within the year following the Transaction, the purchase price on Alaris' remaining financial interest in LifeMark will increase by 4% on each anniversary of the Transaction thereafter.
- Centric must provide Alaris 90 days' notice if it intends to exercise the Purchase Option after the appropriate time has lapsed following the Transaction.

SECTION IV - HOW DOES THIS TRANSACTION BENEFIT ALARIS SHAREHOLDERS?

BENEFIT #1 – SIGNIFICANT GAIN REALIZED ON INVESTMENT

- Upon closing the Transaction, Alaris will have received a total of \$123 million in cash plus residual value of \$65.5 million from the LifeMark Group over a 6 year period with invested capital of \$74 million; this is a total return of 155% over 6 years.
- The first year Distribution of \$6.75 million from LifeMark will continue to grow at 4% each year. If Centric chooses to exercise the Purchase Option in 2 years, Alaris will realize a total cash return over the 8 year life of the Partnership totaling \$202.3 million on invested capital of \$74 million; a 173% return.

As can be seen in the financial details below, the Transaction will provide a significant gain on the original investment, which provides Alaris the opportunity to add significant shareholder value going forward. The numbers also show that if the Purchase Option is exercised in two years, Alaris will realize a second significant gain on its investment and further potential to increase shareholder value. Finally, the financial summary demonstrates that continuing the Partnership with LifeMark provides significant financial benefits to Alaris, regardless of whether or not the Purchase Option is exercised by Centric at some point in the future.

Return on Investment Summary	
Distributions Previously Received from LifeMark Group	\$58.0
Cash from Centric on this Transaction	<u>\$65.0</u>
TOTAL CASH RECEIVED AT CLOSING	\$123.0
Expected distribution from LifeMark (1st 12 months)	\$6.8
Expected distribution from LifeMark (2nd 12 months)	\$7.0
Centric Purchase Option (on 2nd anniversary of closing)	<u>\$65.5</u>
Total Cash Out if Purchase Option is Exercised	\$202.3
Total cumulative capital provided to the LifeMark Group	<u>\$74.0</u>
TOTAL POTENTIAL CASH RETURN	\$128.3
<i>% return</i>	<i>173%</i>

SECTION IV - HOW DOES THIS TRANSACTION BENEFIT ALARIS SHAREHOLDERS?

BENEFIT #2 – POTENTIAL FOR A SIGNIFICANT INCREASE TO DISTRIBUTABLE CASH PER SHARE

	SCENARIO ANALYSIS				
	Pre-transaction	Post-transaction (no new investments, repay debt)	scenario 1 (invest \$15M)	scenario 2 (invest \$40M)	scenario 3 (invest \$65M)
(\$millions except per share data)					
Revenue from Current Partners	\$22.50	\$15.75	\$15.75	\$15.75	\$15.75
Revenue from new investments	\$0.00	\$0.00	\$2.50	\$6.67	\$10.83
Total Revenue	\$22.50	\$15.75	\$18.25	\$22.42	\$26.58
General & Admin Expense	\$2.50	\$2.50	\$2.50	\$2.50	\$2.50
EBITDA	\$20.00	\$13.25	\$15.75	\$19.92	\$24.08
Interest	\$1.64	\$0.00	\$0.00	\$0.08	\$1.64
Distributable Cash	\$18.36	\$13.25	\$15.75	\$19.84	\$22.45
Distributable Cash Per Share	\$1.09	\$0.78	\$0.93	\$1.17	\$1.33
Dividends Payable	\$17.25	\$17.25	\$17.25	\$17.25	\$17.25
Dividends per share	\$1.02	\$1.02	\$1.02	\$1.02	\$1.02
Payout Ratio	94%	130%	109%	87%	77%
Shares outstanding	16.907	16.907	16.907	16.907	16.907
Balance from Transaction Proceeds	\$0.00	\$65.00	\$65.00	\$65.00	\$65.00
Debt Outstanding	\$26.20	\$0.00	\$0.00	\$1.20	\$26.20
Ending Balance of Proceeds	\$0.00	\$38.50	\$23.50	\$0.00	\$0.00
Debt x EBITDA	1.31x	0.00x	0.00x	0.06x	1.09x

The Pre and Post-Transaction summaries, as well as the benefits of receiving cash Proceeds at a 10x multiple and reinvesting the Proceeds at a 6x multiple, are illustrated in the scenarios in the table to the left. The purpose of this table is to demonstrate the possible effects the reinvestment of Proceeds will have on Alaris' financial position. This table is not a forecast but instead an example of possible outcomes management has presented. Descriptions for the information in the table are as follows:

- **Post-Transaction** - Following the Transaction, Alaris will have no debt, debt capacity of \$30 million (or up to 1.70x debt/EBITDA) and total cash on hand of more than \$38.5 million. This positions Alaris for significant future growth and dividend sustainability.
- **Scenario 1** - The result of paying down the current debt and potentially reinvesting a nominal amount of \$15 million.
- **Scenario 2** - The potential reinvestment of \$40M and repayment of nearly all outstanding debt
- **Scenario 3** - The effects of potentially reinvesting the entire \$65 million of Proceeds and maintaining current debt levels


Based on transactions contemplated with new Private Company Partners, as well as with current partners, Alaris management is confident in its ability to reinvest the Proceeds in a timely manner in order to deliver increased DCPS to shareholders. As displayed in the various scenarios, DCPS will increase significantly upon full reinvestment of the Proceeds assuming metrics are similar to those used in the projections and assuming the Proceeds can be reinvested in a timely manner.

Notes to table: Reinvestment of the Proceeds is assumed to be made at a 6.0x multiple (16.7%). The calculation is the amount contributed to the new partnership divided by 6.0, which equals the new annual distribution revenue Alaris will receive from contributing that specific amount to new, or existing private company partners (ie \$15m/6.0=\$2.50m in scenario 1). The "Post-Transaction" column in the table shows the contractual revenue, or "run-rate" revenue, Alaris expects for the 12 months following closing of the Transaction (with the adjustments made to the revenue expected from the LifeMark Group) not actual fiscal 2011 expected revenue. Actual fiscal 2011 revenue will include Pre-Transaction revenue from the LifeMark Group, resulting in higher revenue than that used for the "Post-Transaction" example in the table above. Resets in Distributions from the current Private Company Partners will also affect the revenue line in the "Post-Transaction" column, positively or negatively, depending on their results. This table is intended to show the possible effects various levels of reinvestment of the Proceeds may have on DCPS. It is not a forecast.

SECTION IV - HOW DOES THIS TRANSACTION BENEFIT ALARIS SHAREHOLDERS?

BENEFIT #3 – REBALANCING ALARIS’ REVENUE WILL INCREASE DIVERSIFICATION

Prior to closing of the Transaction, LifeMark’s Distribution to Alaris accounted for 60% of Alaris’ total revenue (figure 1).



Following the Transaction, and assuming no new partnerships are entered into with the \$65m of Proceeds, LifeMark will now account for 43% of Alaris total revenue (figure 2).





Figure 3 assumes Alaris can reinvest the entire \$65 million of Proceeds (at historical levels of 6.0x) resulting in LifeMark’s Distribution now accounting for 25% of Alaris’ total revenue. The reduced weight in LifeMark’s Distribution creates a more diversified, and therefore lower risk, revenue stream for Alaris shareholders.


Figure 3 also displays the result of investing the \$65 million among 3 new Private Company Partners, on an equal weighting and at historical levels of 6.0x. The result is a revenue stream that is closer to Alaris’ long-term goals of not having a single revenue source account for more than 10% of total revenue.



SECTION IV - HOW DOES THIS TRANSACTION BENEFIT ALARIS SHAREHOLDERS?

BENEFIT #4 – INCREASED EARNINGS COVERAGE LEADS TO GREATER CERTAINTY OF ALARIS’ REVENUE

Prior to the Transaction, Alaris’ Pre-Transaction Distribution was covered by the income of the LifeMark Group. Post-Transaction, the Earnings Coverage Ratio on the Distribution will be greater as it will not only be approximately half of the Pre-Transaction Distribution, but will also now be guaranteed by the consolidated income of Centric (which will now include LifeMark’s earnings). This is a great benefit to Alaris’ shareholders as it increases the certainty of revenue from the source, thus increasing the certainty of Alaris’ dividend to its shareholders.



Notes to Graph:

In the example above, “proforma 2010 (LifeMark alone)” is calculated using year ending Dec. 31, 2010 financials from LifeMark and then decreasing the Distribution from \$12.49 (LifeMark Health’s Pre-Transaction Distribution which does not include MEDlchair’s royalty to Alaris) to \$6.75 million, while keeping all other financial metrics as is. “Proforma 2010 (Centric LifeMark combined)” repeats the calculation but now includes Centric’s consolidated year ending Dec. 31, 2010 financial results with LifeMark’s Dec. 31, 2010 financial results.

SECTION IV - HOW DOES THIS TRANSACTION BENEFIT ALARIS SHAREHOLDERS?

BENEFIT #5 – INCREASED VISIBILITY FOR ALARIS’ SHAREHOLDERS

- The LifeMark Group’s Pre-Transaction Distributions were based on the percentage change in “same clinic” and “same store” sales from year over year.
- Volatility in “same clinic” and “same store” sales (albeit were previously low) will now be further reduced as Alaris has built in a guaranteed 4% increase to the annual Distribution received from LifeMark. Upon the first anniversary of closing of the Transaction, Alaris’ Distribution collected from LifeMark will increase by \$.270m to \$7.02m.
- The guaranteed increase creates greater visibility on Alaris’ revenue from LifeMark and thus makes predicting Alaris’ cash flow from this particular Partnership very straight forward.
- By Alaris granting Centric a Purchase Option on its remaining financial interest in LifeMark, it has guaranteed its exit value if the Purchase Option is exercised on the second anniversary of the Transaction. As can be seen in the table below, if the Purchase Option is not exercised upon vesting, the value of Alaris’ financial interest in LifeMark increases by 4% per year thereafter. In either case, Alaris’ residual value in LifeMark is \$65.5 million at a minimum (if the Purchase Option is exercised in the first year it is exercisable) and greater than \$65.5 million if the Purchase Option is exercised in any year following the first year in which it is exercisable. This creates significant visibility on Alaris’ potential exit value as it relates to its Partnership with LifeMark.

Summary of Distribution Growth and Purchase Option Value					
	Year 1	Year 2	Year 3	Year 4	Each year thereafter
Exit Value	Purchase Option can't be exercised	Purchase Option can't be exercised	\$65.5	\$68.12 ↑ 4%	Previous value +↑ 4%
Annual Distribution	\$6.75 ↑ 4%	\$7.02 ↑ 4%	\$7.30 ↑ 4%	\$7.59 ↑ 4%	Previous value +↑ 4%



SECTION V - PROVING THE BENEFIT OF ALARIS' CAPITAL STRUCTURE TO PRIVATE COMPANIES

ALARIS MARKETS ITSELF TO PRIVATE COMPANIES USING THESE POINTS:

1. Alaris offers passive non-voting preferred equity
2. Alaris has an indefinite investment horizon without the need for a forced exit
3. Alaris has a lower participation in growth than traditional private equity

HAVE THESE POINTS BEEN PROVEN? YES

1. Alaris has been a partner with LifeMark for 6 years. While Alaris has not had any equity votes and has not been active in the day-to-day management of LifeMark, we have been a consistently supportive financial partner by providing acquisition capital on seven separate occasions. This has allowed LifeMark management to grow from 35 clinics 6 years ago to more than 120 clinics today, without giving up any operating control or diluting their equity interest.
2. When LifeMark management approached Alaris with a desire to crystalize their investment, Alaris worked with LifeMark and Centric to find a transaction that worked for the parties involved. Alaris made the Transaction work by maintaining half of its financial interests in LifeMark, which made the Transaction more affordable for Centric and which also allowed Alaris to continue to receive Distributions from a consistent source of revenue.
3. Alaris participated in a lower percentage of LifeMark's growth over the past 6 years (figure 1). Because of this, Alaris' Distribution now accounts for less than 50% of LifeMark's economic interest in 2011F, after initially accounting for more than 80% in 2005. This decrease of economic interest was despite Alaris investing an additional 6 tranches of capital to fund LifeMark's acquisition program over that time period. This creative structure has allowed common equity holders in LifeMark to crystalize their investment at a significant return.



APPENDIX

FINANCIAL SUMMARY AND TIMELINE OF THE RELATIONSHIP WITH LIFEMARK AND MEDICHAIR

(all data in \$millions)

Date	Original Contribution	Multiple	Distribution amount per Contribution
31-Dec-04	\$35.00	6.18x	\$5.66
15-Jun-05	\$1.50	6.25x	\$0.24
30-Sep-05	\$6.50	6.50x	\$1.00
1-Oct-05	\$2.50	6.49x	\$0.39
1-Aug-06	\$7.50	7.50x	\$1.00
31-Jul-09	\$1.00	5.52x	\$0.18
1-Oct-09	\$12.00	5.89x	\$2.04
22-Apr-10	\$8.00	7.00x	\$1.14
TOTALS	\$74.00		\$11.65
Pre-Transaction 2011 Distribution			\$13.50
Organic growth in distributions			15.9%

for MEDICHAIR acquisition

Summary of Distributions Received from the LifeMark Group	
Year	(\$millions)
2005	\$6.12
2006	\$7.50
2007	\$8.31
2008	\$8.60
2009	\$9.56
2010	\$12.53
2011	\$5.61
Cash Distributions to date	\$58.23
Cash from Transaction	\$65.00
Total cash to date	\$123.23

(5 months)

Note:

The table above lists the contributions Alaris has made to the LifeMark Group since December 2004 and the Distribution associated with each separate contribution amount. The total contributions of \$74 million represent the total cost to Alaris while \$11.65 million represents to original value of all Distributions associated with the original contributions. Today's Pre-Transaction Distribution is \$13.50. Therefore, the Distributions Alaris receives from the LifeMark Group grew organically by 15.9% over the past 6 years.

Note:

The Summary of Distributions table displays the actual Distribution amounts Alaris has received from the LifeMark Group to date and the cash Proceeds it is receiving from the Transaction. The total cash received is the dollar amount Alaris will have actually taken out of the Partnership as of closing of the Transaction.

CONTACT INFORMATION

CURTIS KRAWETZ

Manager of Investor Relations & Investment Analyst

Alaris Royalty Corp.

Ph 1-403-221-7305

ckrawetz@alarisroyalty.com

OR

RECEPTION

Ph 1-403-228-0873

Fax 1-403-228-0906

ALARIS ROYALTY CORP.

232, 2031 33rd Avenue SW

Calgary AB, Canada

T2T 1Z5

www.alarisroyalty.com

